SAMSUNG-ELECTRONICS
17.1.2023 10:06:47 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 200-megapixel (MP) image sensor, the ISOCELL HP2, with improved pixel technology and full-well capacity for stunning mobile images in tomorrow’s premium smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005554/en/
Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones (Graphic: Business Wire)
"The Samsung ISOCELL HP2 harnesses Samsung's high-resolution image sensor technologies and know-how at the cutting edge for epic details," said JoonSeo Yim, Executive Vice President of Sensor Business Team at Samsung Electronics. "Our leadership comes from innovative pixel technologies that allow our sensors to go beyond the number and size of pixels. We will continue to open new horizons and solidify our presence in the expanding ultra-high-resolution sensor market."
The ISOCELL HP2 packs 200-million 0.6-micrometer (μm) pixels in a 1/1.3” optical format, a sensor size that is widely used in 108MP main smartphone cameras. This enables consumers to enjoy even higher resolutions in the latest high-end smartphones without larger camera bumps in their devices.
With Samsung’s advanced pixel-binning technology, Tetra2pixel, the HP2 adds more versatility to the camera as it simulates different pixel sizes to accommodate varying lighting levels. When in low-lit environments, the sensor transforms either into a 1.2μm 50MP or 2.4μm 12.5MP image sensor by binding four to 16 neighboring pixels. For fuller 8K video, approximately at 33MP, the HP2 switches to 1.2μm 50MP mode to minimize cropping and capture more of the scene. Filming 8K at 30 frames-per-second (fps), a wide field of view along with bigger pixel size can produce sharp cinematic videos.
Washed out pictures from brightly lit environments can be significantly reduced with the HP2, thanks to Samsung’s new Dual Vertical Transfer Gate (D-VTG) technology. In a photo diode within each pixel, a voltage transfer gate is placed on the bottom to transport electrons from the pixels to the logic layer. With high precision, D-VTG adds a second transfer gate in the pixel, boosting the pixel’s full-well capacity by more than 33 percent. With more electrons stored and efficient signal transfers, this method can reduce overexposure and enhance color reproduction, especially in bright light conditions
In low-lit settings, the HP2’s auto-focusing is taken to the next level with Super QPD, which allows the sensor to use all its 200-million pixels for focusing agents. The ample amount of focusing agents are grouped by four adjacent pixels to recognize both horizontal and vertical pattern changes that delivers faster and more accurate auto-focusing. Utilizing the rich pattern data along with the sheer number of reference points, the new sensor is capable of fast auto-focusing, even in a dimly lit environment.
For superb HDR performance, Samsung is introducing the DSG feature for the first time in 50MP mode which applies two separate conversion values to the analog signal received at the pixel level. In addition, the Smart-ISO Pro, an HDR solution that merges different levels of ISO readouts from a single exposure, allows the camera to take 12.5MP images and 4K at 60fps video in HDR.
The Samsung ISOCELL HP2 has entered mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005554/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
